HSBC initiated coverage of Bluebird Bio with a Buy rating and $4.21 price target. The analyst initiated coverage of 11 U.S. biopharma and healthcare companies and sees six names that are differentiated with drivers that will create long-term value. The risk/rewards look attractive for those companies with revenue opportunities and low exposure to lower R&D productivity, loss of exclusivity and regulation, the analyst tells investors in a research note. blue‘>HSBC believes the biotech sector in general will get a “relative lift from favorable” Inflation Reduction Act dynamics, while segments like animal health are “completely unaffected.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLUE:
- Bluebird Bio: FDA advisory committee not scheduling meeting for lovo-cel
- Bluebird Bio reports Q2 EPS 67c, consensus 71c
- BLUE Earnings this Week: How Will it Perform?
- Bank of America Says These 2 Stocks Could Double Your Money — Here’s Why They Could Rally
- Largest borrow rate increases among liquid names